• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172050 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ) \1 ?* ^1 b4 t
6 _/ ^/ d1 n# e& P8 [

% g; R6 ~; A6 U4 X- y% k+ ^Sub-category:
- Q- e% e( Q/ Y' |3 x+ nMolecular Targets & y9 A7 g& z' M2 v1 \& u

. o2 I* B8 u0 V0 H+ e, ~, a1 f+ t( _) Q9 T- S7 g
Category:0 h/ ]! {+ |  T6 ?/ T2 k
Tumor Biology & o3 e/ t- e7 a
- ?" U0 y8 K; ]6 v* v; |2 |
. j& O6 [  g+ s! i! r
Meeting:
& d1 U0 i9 P3 f: L2011 ASCO Annual Meeting
9 K/ C" a$ [7 m- F4 c( H& v4 ?% K1 S" B$ i6 a% }4 m

  o8 C8 J9 o. r$ l. T7 C1 XSession Type and Session Title:/ j0 H1 |# C  {8 H5 H# X$ `
Poster Discussion Session, Tumor Biology
. n; y1 o5 E) x( y# [
, s% t' c8 v$ ]6 v* Z+ b3 K; t4 h, D  H1 r1 e
Abstract No:
: l* ~/ z; j$ e" S& k10517
* U3 c; g  ]) X
$ p- |- J  k8 H) M  |* l7 m8 e" h: N* @( S! X  u  K# ?/ L
Citation:9 L! `0 B. `# Q7 Z. i& |5 s
J Clin Oncol 29: 2011 (suppl; abstr 10517) 1 Y4 j' r: p& V% N& Z% u! U: n- g

6 `# e. L3 H7 W" C# I1 f4 E1 M
# H1 @3 O3 I; x. yAuthor(s):
% J: e$ N3 A, P( g: I# N' U2 kJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 4 k; u- V1 l9 M& @( I) e

4 o  j$ K4 R; a- ?* }& q8 r3 o" L! Q: F6 x, _3 Z
! ~4 |% u3 y6 K' G9 N
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.2 N# u- E$ [3 f/ T
. J; s+ T# F. W9 ^1 I
Abstract Disclosures; |  N/ ]  k$ g" h/ ~
$ @, D3 B/ U5 i* o
Abstract:
$ q3 A/ ~' |3 |' r' O% G
# `9 M% ?# |' v$ B/ M! f: `; E
6 ?+ c* L9 Y) ]: bBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation./ h1 V  x. y) u1 E/ j
; t4 f8 P. k7 t8 e3 {3 f
' g( n+ u3 N* e8 ?! c
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
+ s7 J4 q, U1 X) Y0 p! e/ X/ |没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

( U, G4 k5 Z; ~7 D# D化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 & H& U! ^8 W/ x8 G3 \
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。1 ^' g/ j0 V% ?, T
ALK一个指标医院要900多 ...
$ t6 ^4 ?2 O: A3 X
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?# _# {' T/ f  a* b
1 F7 K3 f/ T# d2 T7 m, J
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表